Results 91 to 100 of about 487,301 (268)
Prediction of Chemosensitivity in Multiple Primary Cancer Patients Using Machine Learning
, 2021 Background/aim: Many cancer patients face multiple primary cancers. It is challenging to find an anticancer therapy that covers both cancer types in such patients.
김기열, 장향란
core +1 more source
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Azatyrosinamides: Novel RAS-related anticancer agents
, 2013 [[abstract]]Background: We previously reported on the design and synthesis of novel azatyrosinamide derivatives selective for ras-transformed NIH3T3 cells and with improved toxicity over azatyrosine. This study was aimed at investigating the mechanism of
Wang, CL;Lee, O;Huang, CF;Li, EIC;Teng, CM;Pan, SL;Lian, JF;Chang, FS;Liou, JP;Wang, HP
core
Polysaccharide based anticancer prodrugs
, 2009 So far, polysaccharides have been widely used in pharmaceutical technology as first choice excipients for production of traditional formulations. Nevertheless, in the recent years these natural and semisynthetic macromolecules have been addressed for new
SALMASO, STEFANO +5 more
core +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
, 2002 Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug ...
Kerr, David J., Baguley, Bruce C.
core
Tumor B‐cell infiltration in platinum‐treated advanced muscle‐invasive urothelial carcinoma
Molecular Oncology, EarlyView.Bladder tumors with higher pretreatment memory B‐cell infiltration were linked to longer survival after cisplatin chemotherapy, but not carboplatin. These tumors also showed more organized immune structures (tertiary lymphoid structures) and a shared pro‐inflammatory B‐cell‐rich community, suggesting that memory B cells may help identify patients most ...
Konrad Stawiski +10 more
wiley +1 more source
Cell-Based Anticancer Drug Delivery Systems
, 2016 Most explored approaches to developing cell-based drug delivery systems (DDSs) are encapsulation of the drug into the cells, cell surface modification, genetic modification of cells to secrete desired therapeutic proteins, and generating new biosynthetic
Bosnakovski, Darko +5 more
core +1 more source
Molecular Oncology, EarlyView.Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski +12 more
wiley +1 more source
A Database of Drug Repurposing Clinical Trials in Oncology
Frontiers in Pharmacology, 2021 Pan Pantziarka +3 more
doaj +1 more source